Recently, Jilin Laiwo Medical Technology Co., Ltd., with its profound accumulation and unremitting innovation in the field of hemodialysis treatment, successfully obtained the Class III medical device registration certificate issued by the National Medical Products Administration for its independently developed new product - hemodialysis concentrate (A liquid B dry powder). This achievement not only marks an important breakthrough for the company in the field of hemodialysis treatment, but also brings good news to the vast number of dialysis patients.

Hemodialysis concentrate
       Levo Medical R&D and production is an ultra pure blood dialysis fluid, which minimizes the presence of thermal substances in the dialysis fluid and is free from microbial contamination.
       Hemodialysis concentrate is an important component of hemodialysis treatment. Dialysis patients are at high risk of hospital acquired infections due to their weakened immune system, which can lead to local or systemic infections. How to reduce the infection of dialysis patients, improve the quality of dialysis, and increase the survival rate has made the demand for high-quality dialysis fluid particularly urgent in clinical practice.

Product Features

A concentrated solution is acidic and contains components such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, acetic acid, etc

B dry powder is alkaline, mainly composed of sodium bicarbonate

       Ultra pure hemodialysis concentrate minimizes the presence of pyrogens in the dialysate and is free from microbial contamination. It can significantly reduce the occurrence of chronic inflammation and dialysis related amyloidosis, reduce oxidative stress and cardiovascular disease incidence, effectively improve the nutritional status and quality of life of hemodialysis patients, protect residual renal function of hemodialysis patients, significantly improve dialysis quality, and improve long-term survival rate of patients.

Product advantages
1. Ultra pure dialysate is safer and more stable
2. Significantly reduce and improve the patient's micro inflammatory response
3. Increase sensitivity to EPO
4. Reduce β 2-microglobulin levels and dialysis amyloidosis (carpal tunnel syndrome)
5. Improving the nutritional status of dialysis patients
6. Protecting residual renal function

Product scope of application
       This product is suitable for hemodialysis treatment of patients with acute and chronic renal failure. Hemodialysis is the main treatment method for maintaining the life of patients with uremia, which is mixed with dialysis water in proportion using a hemodialysis machine. Its main function is to correct electrolyte and acid-base balance disorders in dialysis patients, and eliminate metabolic waste from the body.
       In the future, Laiwo Medical will continue to uphold the corporate spirit of "healthy life, Laiwo quality", continuously increase research and development investment and technological innovation, and provide patients with safer, more effective, and convenient medical products. At the same time, we will actively respond to the national policy call for the development of the medical and health industry, and contribute more to promoting the development of China's medical and health industry.